Shares of Boston Scientific Co. (NYSE:BSX – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $77.41.
Several research firms have weighed in on BSX. Robert W. Baird boosted their target price on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Evercore ISI boosted their target price on shares of Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $82.00 target price on shares of Boston Scientific in a research report on Tuesday, June 18th. UBS Group boosted their target price on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Finally, Royal Bank of Canada boosted their target price on shares of Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th.
Check Out Our Latest Analysis on BSX
Insider Activity at Boston Scientific
Institutional Investors Weigh In On Boston Scientific
A number of large investors have recently modified their holdings of BSX. LPL Financial LLC grew its holdings in shares of Boston Scientific by 5.1% during the third quarter. LPL Financial LLC now owns 362,592 shares of the medical equipment provider’s stock worth $19,145,000 after buying an additional 17,463 shares in the last quarter. Synovus Financial Corp grew its holdings in shares of Boston Scientific by 171.2% during the third quarter. Synovus Financial Corp now owns 16,200 shares of the medical equipment provider’s stock worth $855,000 after buying an additional 10,226 shares in the last quarter. Bamco Inc. NY grew its holdings in shares of Boston Scientific by 44.0% in the third quarter. Bamco Inc. NY now owns 112,300 shares of the medical equipment provider’s stock valued at $5,929,000 after purchasing an additional 34,300 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Boston Scientific by 106.5% in the third quarter. Tower Research Capital LLC TRC now owns 90,036 shares of the medical equipment provider’s stock valued at $4,754,000 after purchasing an additional 46,425 shares during the period. Finally, Fred Alger Management LLC grew its holdings in shares of Boston Scientific by 26.1% in the third quarter. Fred Alger Management LLC now owns 2,596,472 shares of the medical equipment provider’s stock valued at $137,094,000 after purchasing an additional 537,992 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Boston Scientific Stock Down 0.6 %
Shares of Boston Scientific stock opened at $76.11 on Thursday. The firm’s 50 day moving average price is $75.16 and its 200-day moving average price is $67.96. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. Boston Scientific has a 52-week low of $48.35 and a 52-week high of $77.99. The company has a market cap of $111.66 billion, a P/E ratio of 63.96, a PEG ratio of 2.65 and a beta of 0.78.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The firm had revenue of $3.86 billion for the quarter, compared to the consensus estimate of $3.68 billion. On average, sell-side analysts predict that Boston Scientific will post 2.32 EPS for the current fiscal year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
- Five stocks we like better than Boston Scientific
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- AbbVie Stock: A Perfect Dip for Investors to Buy
- CD Calculator: Certificate of Deposit Calculator
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- How to Choose Top Rated Stocks
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.